Secondary metabolites from the leaves of *Terminalia myriocarpa* and their α-glucosidase inhibitory potential

Ann G. Boulis¹, Soheir M. El Zalabani², Neveen S. Ghaly¹, Omar M. Sabry²*, May A. El-Manawy³, Ahmed H. Afifi², Farouk R. Melek¹

¹Chemistry of Natural Compounds Department, National Research Centre, Dokki, Giza, 12622, Egypt.
²Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt.
³Pharmacognosy Department, National Research Centre, Dokki, Giza, 12622, Egypt.

ARTICLE HISTORY
Received on: 26/09/2023
Accepted on: 20/01/2024
Available Online: 05/03/2024

Key words: *Terminalia myriocarpa*, triterpenoids, tannins, flavonoids, α-glucosidase inhibitory activity, docking study.

ABSTRACT
The objective of this study is to investigate the chemical composition of the leaves of *Terminalia myriocarpa* and to evaluate their α-glucosidase inhibitory activity aiming to be used as a safe antidiabetic. Consequently, 10 compounds were isolated using column and preparative thin-layer chromatographic techniques and identified as alphitolic acid, isovitexin, flavogallonic acid, nigaichigoside F1, quercetin, quadranoside IV, rosamultin, 19α-hydroxyasiatic acid, asiatic acid, and arjunic acid. Structure elucidation was based on chemical (acid hydrolysis) and spectroscopic (UV, ¹H, and ¹³C-NMR) analyses and findings were confirmed through comparison with published data. The α-glucosidase inhibitory activity of the methanol extract fractions and compounds isolated therefrom was evaluated *in vitro* alongside that of acarbose (positive control). Results revealed that quercetin and flavogallonic acid were significantly active with half-maximal inhibitory concentrations (IC₅₀) equal to 7.5 ± 0.09 and 21.0 ± 1.4 µM, respectively. Furthermore, the interaction of flavogallonic acid with α-glucosidase enzyme was verified by docking experiment. Accordingly, quercetin and flavogallonic acid could be considered safer natural alternatives to the currently available α-glucosidase inhibitors.

INTRODUCTION

*Terminalia myriocarpa* (East Indian Almond) is a tall evergreen tree growing up to 40 m, native to eastern Asia, southern China, northeast India, Nepal, Bhutan, Myanmar, Thailand, Malaysia, Indonesia, Laos, and Vietnam [1]. Several compounds were previously reported from the leaves of *T. myriocarpa*, including cinnamic acid, *trans*-ferulic acid, syringic acid, gallic acid, methyl gallate, ethyl gallate, 2,3-(S)-HHDP-D-glucose, ellagic acid, flavogallonic acid, methyl-(S)-flavogallonate, *α/β*-punicalagin, epigallocatechin gallate, vitexin, isovitexin, orientin, iso-orientin, kaempferol-3-O-β-D-rutinoside, rutin, neosaponarin, quercetin, and myricetin [2–4].

Moreover, β-sitosterol, β-amyrin, oleanolic acid, betulinic acid, maslinic acid, and arjunolic acid were separated from the bark of *T. myriocarpa* [5]. From the standpoint of bioactivity, ellagic acid and methyl-(S)-flavogallonate, isolated from *T. myriocarpa* leaves, were found to possess antioxidant and anti-inflammatory activities [3].

Diabetes mellitus is a widespread metabolic disorder, which affects about 422 million people globally [6]. The most prevalent form of diabetes, type 2 (noninsulin-dependent diabetes mellitus, or T2DM), is characterized by a relative insulin shortage caused by the concomitant presence of insufficient insulin production, tissue insulin resistance, and insufficient compensatory mechanisms [7]. Ineffective glycemic control in T2DM patients can lead to serious retinal, renal, and cardiovascular problems, as well as a sharp decline in life expectancy [8]. Limiting postprandial hyperglycemia by inhibiting polysaccharide-digesting enzymes in the proximal small intestine, including α-glucosidase, and thus reducing glucose absorption from the gut, is a treatment approach for
The development of safer α-glucosidase inhibitors from natural sources for the treatment of T2DM has received a lot of attention due to the unpleasant side effects associated with the currently available α-glucosidase inhibitors on the market [6]. Some Terminalia species were reported to contain several α-glucosidase inhibitory constituents, including 23-O-galloyljuarjunolic acid, 23-O-galloyljuarjunolic acid-28-O-β-D-glucopyranosyl ester, 1,2,3,6-tetra-O-galloyl-4-O-cinnamoyl-β-D-glucose, and 4-O-(2"",4"")-di-O-galloyl-α-L-rhamnosyl) ellagic acid isolated from Terminalia chebula fruits, alongside rutin, narcissin, chebulagic acid, and corilagin isolated from Terminalia macroptera leaves [10–12]. To the best of our knowledge, however, there have not been any additional discoveries about the α-glucosidase inhibitory capacity of T. myriocarpa leaf extract.

As a part of our continuous interest in exploring bioactive phytoconstituents, we investigated T. myriocarpa leaf extract aiming at identifying its α-glucosidase inhibitory constituents.

MATERIALS AND METHODS

Plant material

The leaves of T. myriocarpa Van Heurck & Müll. Arg. were collected from the Zoo Garden, Giza, Egypt, in March 2020, and identified by Ms. Therese Labib, the taxonomical consultant at Al-Orman and Al-Qubba Botanical Gardens. A voucher specimen, with the identifier M165, was deposited in the herbarium of the National Research Centre, Giza, Egypt.

General experimental procedures

Column chromatography (CC) was performed using silica gel 60 (E-Merck, Darmstadt, Germany), Sephadex LH-20 (Pharmacia Fine Chemicals AB Uppsala, Sweden), and Diaion HP-20 (Sigma-Aldrich, St. Louis, MO). Preparative thin-layer chromatography (PTLC) and analytical thin-layer chromatography (TLC) were carried out using silica gel and polyamide (E-Merck, Darmstadt, Germany). Chromatograms were first observed under ultraviolet (UV) light, before being treated with ferric chloride reagent, or sulfuric acid reagent (20% H2SO4). TLC spots were first observed under ultraviolet (UV) light, before being treated with ferric chloride reagent, or sulfuric acid reagent (20% H2SO4). Chromatograms were first observed under ultraviolet (UV) light, before being treated with ferric chloride reagent, or sulfuric acid reagent (20% H2SO4). Chromatograms were first observed under ultraviolet (UV) light, before being treated with ferric chloride reagent, or sulfuric acid reagent (20% H2SO4). Chromatograms were first observed under ultraviolet (UV) light, before being treated with ferric chloride reagent, or sulfuric acid reagent (20% H2SO4). Chromatograms were first observed under ultraviolet (UV) light, before being treated with ferric chloride reagent, or sulfuric acid reagent (20% H2SO4). Chromatograms were first observed under ultraviolet (UV) light, before being treated with ferric chloride reagent, or sulfuric acid reagent (20% H2SO4).

Extraction and isolation of the leaf constituents

Fresh T. myriocarpa leaves (10 kg) were air-dried and powdered to yield 2.2 kg of leaf powder (22%). The obtained dry powder was thoroughly extracted thrice, at room temperature, by maceration with 100% methanol (MeOH), followed by 70% aqueous MeOH twice. A portion (200 g) of the brownish–green residue (258 g), resulting from solvent evaporation of the combined leaf extract, was suspended in distilled water (2 l) and then partitioned with dichloromethane (CH2Cl2) (21 × 5) followed by ethyl acetate (EtOAc) (21 × 5). The solvent in each fraction was separately evaporated under vacuum to dryness.

An aliquot (20 g) of the dried CH2Cl2 fraction (24 g) was subjected to silica gel CC (800 g). The gradient elution system consisted of a mixture of n-hexane and EtOAc (93:7, 90:10, 85:15, 80:20, 75:25, 50:50, 20:80, and 0:100, v/v), yielding fractions D1–D8, respectively. Fraction D5 (345 mg) was subjected to Sephadex LH-20 CC (50 g) and eluted with CHCl3–MeOH (3:2, v/v) to afford subfractions D5.1–D5.4. Subfraction D5.3 (86 mg) was chromatographed using silica gel PTLC plates [chloroform (CHCl3)–MeOH, 15:1, v/v, triple development] to give crude alphaltic acid (1) (42 mg) which was further purified on a Sephadex LH-20 column (30 g) eluted with MeOH to yield pure 1 (37 mg).

A portion (25 g) of the EtOAc fraction (36 g) was chromatographed using Diaion HP-20 CC (200 g) and eluted with a mixture of MeOH—distilled water (H2O) (0:100, 25:75, 40:60, 50:50, 60:40, 70:30, 80:20, and 100:0, v/v) to give fractions E1–E8, respectively. Fraction E3 (2.5 g) was subjected to a Sephadex LH-20 column (50 g) eluted with MeOH to give subfractions E3.1–E3.3. Using polyamide PTLC plates developed with MeOH–H2O (15:1, v/v), subfraction E3.2 (84 mg) afforded crude isovitexin (2) (25 mg) which was further purified on a Sephadex LH-20 column (30 g) eluted with MeOH to provide pure 2 (20 mg). Subfraction E3.3 (104 mg) was loaded on a Sephadex LH-20 column (50 g) eluted with MeOH to afford flavogallonic acid (3) (77 mg). Fraction E4 (1.7 g) was subjected to Sephadex LH-20 CC (50 g) eluted with MeOH to give subfractions E4.1–E4.6. Separation of subfraction E4.2 (301 mg) using repeated silica gel PTLC with CHCl3–MeOH (2:1, v/v) yielded crude nigaichigoside F1 (4) (74 mg) which was further purified using a Sephadex LH-20 column (30 g) eluted with MeOH to afford pure 4 (65 mg). Subfraction E5 (2.6 g) was subjected to a Sephadex LH-20 column (50 g) and eluted with MeOH to give subfractions E5.1–E5.5. Subfraction E5 (144 mg) was chromatographed on a silica gel column (50 g) using a gradient mixture of CHCl3–MeOH (10:1 and 7:1, v/v) to yield crude quercetin (5) (24 mg) which was further purified by Sephadex LH-20 CC (30 g) using MeOH as eluent to afford pure 5 (19 mg). Fraction E6 (2.3 g) was loaded on a Sephadex LH-20 column (100 g) and eluted with MeOH to afford subfractions E6.1–E6.3. Subfraction E6.2 (270 mg) was subjected to repeated silica gel PTLC using CHCl3–MeOH (5:1, v/v, double development) to give crude quandranoside IV (6) (73 mg), rosamultin (7) (78 mg), and 19α-hydroxyasatic acid (8) (27 mg). Each compound was separately loaded on a Sephadex LH-20 column (30 g) eluted with MeOH to afford pure 6 (65 mg), 7 (68 mg), and 8 (22 mg). Fraction E7 (370 mg) was subjected to CC on a Sephadex LH-20 column (50 g) eluted with MeOH to give subfractions E7.1–E7.4. Repeated chromatography of subfraction E7.2 (197 mg) using silica gel PTLC plates developed with CHCl3–MeOH (5:1, v/v) yielded crude asiatic acid (9) (56 mg) and arjunic acid (10) (44 mg) which were individually purified using Sephadex LH-20 CC (30 g) eluted with MeOH to give pure 9 (48 mg) and 10 (39 mg).

Identification of the isolated compounds

The structures of compounds 1–10 (Fig. 1) were established, based on their spectral data, as follows.
**Alphitolic acid (1)**

$^1$H-NMR (CD$_{3}$OD, ppm): 4.69 (1H, d, J = 2.6 Hz, H-29a), 4.54 (1H, br s, H-29b), 3.60 (1H, m, H-2), 2.90 (1H, d, J = 9.6 Hz, H-3), 1.68 (3H, s, Me-30), 1.01 (3H, s, Me-27), 0.99 (3H, s, Me-23), 0.98 (3H, s, Me-26), 0.91 (3H, s, Me-25), and 0.78 (3H, s, Me-24). $^1$C-NMR (APT) (CD$_{3}$OD, ppm): 153.4 (C, C-20), 109.5 (CH$_3$, C-29), 84.6 (CH, C-3), 69.9 (CH, C-2), 59.1 (C, C-17), 57.0 (CH, C-5), 52.3 (CH, C-9), 51.1 (CH, C-18), 43.8 (C, C-14), 42.2 (C, C-8), 40.7 (C, C-4), 39.6 (C, C-10), 39.5 (CH, C-13), 39.3 (CH$_3$, C-22), 35.7 (CH$_3$, C-7), 33.2 (CH$_3$, C-16), 32.4 (CH$_3$, C-21), 30.9 (CH$_3$, C-15), 29.3 (CH$_3$, C-23), 27.2 (CH$_3$, C-12), 22.5 (CH$_3$, C-11), 19.9 (CH$_3$, C-30), 19.7 (CH$_3$, C-6), 18.1 (CH$_3$, C-25), 17.4 (CH$_3$, C-24), 17.1 (CH$_3$, C-26), and 15.2 (CH$_3$, C-27).

**Isovitexin (2)**

UV spectral data (CH$_3$OH, nm): 272, 335; $^1$H-NMR (CD$_3$OD, ppm): 7.85 (2H, d, J = 8.8 Hz, H-2',6'), 6.93 (2H, d, J = 8.8 Hz, H-3',5'), 6.61 (1H, m, H-3), 6.62 (1H, s, H-8), 4.90 (1H, d, J = 10.0 Hz, H-1''), 4.16 (1H, t, J = 9.1 Hz, H-2''), 3.88 (1H, dd, J = 12.1, 2.3 Hz, H-6'a), 3.74 (1H, dd, J = 12.1, 5.2 Hz, H-6''b), 3.49–3.48 (2H, m, H-3',4'), and 3.47 (1H, m, H-5''). $^1$C-NMR (CD$_3$OD, ppm): 183.9 (C-4), 166.3 (C-2), 166.1 (C-7), 163.0 (C-4'), 162.1 (C-5), 158.9 (C-9), 129.5 (C-2',6''), 123.1 (C-1'), 117.2 (C-3',5'), 109.5 (C-6), 104.9 (C-10), 103.8 (C-3), 95.7 (C-8), 82.7 (C-5''), 80.4 (C-3''), 75.5 (C-1''), 72.6 (C-2''), 71.9 (C-4''), and 62.9 (C-6').

**Flavogallonic acid (3)**

UV spectral data (CH$_3$OH, nm): 213, 257, 269sh., 354; $^1$H-NMR (CD$_3$OD, ppm): 7.52 (1H, s, H-5''), 7.24 (1H, s, H-6''), 3.97 (3H, s, Me-29), 3.68 (1H, s, H-5'), 3.37–3.33 (4H, m, H-3), 3.32 (1H, dd, J = 9.6 Hz, H-2), 1.34 (3H, s, CH$_3$-7), 1.21 (3H, s, CH$_3$-27), 0.93 (3H, d, J = 6.6 Hz, CH$_3$-30), 0.78 (3H, s, CH$_3$-24), and 0.70 (3H, s, CH$_3$-26). $^1$C-NMR (APT) (CD$_3$OD, ppm): 178.6 (C, C-28), 139.8 (C, C-13), 129.6 (CH, C-12), 95.9 (CH, C-1'), 78.6 (CH, C-3), 78.4 (CH, C-5), 78.4 (CH, C-3'), 73.9 (CH, C-2'), 73.6 (C, C-19), 71.2 (CH, C-4'), 69.8 (CH, C-2), 66.6 (CH$_3$, C-23), 62.4 (CH$_3$, C-6), 55.0 (CH, C-18), 49.6 (C, C-17), 49.2 (CH, C-9), 48.6 (CH, C-5), 47.2 (CH$_3$, C-1), 44.2 (C, C-8), 43.0 (CH, C-20), 42.9 (C, C-14), 41.4 (C, C-4), 39.1 (C, C-10), 38.4 (CH$_3$, C-22), 33.6 (CH$_3$, C-7), 29.7 (CH$_3$, C-15), 27.3 (CH$_3$, C-21), 27.2 (CH$_3$, C-29), 26.6 (CH$_3$, C-16), 24.9 (CH$_3$, C-11), 24.9 (CH$_3$, C-27), 19.4 (CH$_3$, C-6), 17.8 (CH$_3$, C-25), 17.8 (CH$_3$, C-26), 16.8 (CH$_3$, C-30), and 14.0 (CH$_3$, C-10).

**Quercetin (5)**

UV spectral data (nm): 256, 272sh., 372 (CH$_3$OH), 7.73 (1H, d, J = 2.1 Hz, H-2'), 7.62 (1H, dd, J = 8.5, 2.1 Hz, H-6''), 6.88 (1H, d, J = 8.5 Hz, H-5'').

Figure 1. Structures of compounds isolated from *T. myricarpa* leaves.
2.61 (1H, br s, H-18), 1.32 (3H, s, CH-27), 1.20 (3H, s, CH-29), 1.03 (3H, s, CH-25), 0.92 (3H, d, J = 6.4 Hz, CH-30), 0.86 (3H, s, CH-26), 0.71 (3H, s, CH-29), 14.0 (CH-3).\textsuperscript{11}C-NMR (APPT) (CD\textsubscript{2}OD, ppm): 180.6 (C, C-28), 141.2 (C, C-13), 128.7 (CH, C-12), 78.7 (CH, C-3), 74.2 (C, C-19), 69.8 (CH, C-2), 66.9 (CH\textsubscript{3}, C-23), 55.8 (CH, C-18), 50.1 (C, C-17), 48.8 (CH, C-9), 48.6 (CH, C-5), 47.7 (CH\textsubscript{3}, C-1), 44.2 (C, C-8), 43.2 (CH, C-20), 42.9 (C, C-14), 41.2 (C, C-4), 39.4 (CH\textsubscript{2}, C-22), 39.2 (C, C-10), 33.6 (CH, C-7), 29.2 (CH, C-15), 27.9 (CH\textsubscript{3}, C-21), 27.5 (CH\textsubscript{3}, C-29), 27.2 (CH\textsubscript{3}, C-16), 24.9 (CH\textsubscript{3}, C-11), 24.4 (CH\textsubscript{2}, C-27), 19.5 (CH\textsubscript{3}, C-6), 17.7 (CH, C-26), 17.5 (CH\textsubscript{3}, C-25), 16.9 (CH\textsubscript{3}, C-30), and 14.0 (CH\textsubscript{3}, C-24).

\textbf{Evaluation of the \(\alpha\)-glucosidase inhibitory activity}

In phosphate buffer saline (pH 6.8), \(\alpha\)-glucosidase from \textit{Saccharomyces cerevisiae} (SIGMA G5003-100UN) was prepared at a concentration of 0.2 U/ml. \(\alpha\)-Glucosidase (60 \(\mu\)l, 0.2 U/ml) was combined with each sample (10 \(\mu\)l) at different
concentrations (0.3–700 ppm in the final volume). The mixture was then incubated for 20 minutes at 37°C in a 96-well plate. Subsequently, p-nitrophenyl-D-glucopyranoside (p-NPG) (SIGMA N1377) (150 µl, 1.25 mM) was added to each mixture and incubated for 20 minutes at 37°C, then 50 µl of 2 g/l sodium hydroxide (NaOH) was added to terminate the reaction. The amount of bright yellow p-nitrophenol released from the colorless p-NPG was measured spectrophotometrically at 405 nm to evaluate the activity of the α-glucosidase enzyme. Acarbose was utilized as a positive control, and a reaction mixture with 10 µl of buffer solution in place of the test entity was utilized as a negative control. For blank, p-nitrophenyl-α-D-glucopyranoside with buffer solution was added instead of the enzyme [14,15].

Docking study

The chemical structure of the screened compound was sketched using ChemBioDraw Ultra 14.0 software (CambridgeSoft corporation), and then energy was minimized by MMFF94x force field in the gas phase to a gradient of 0.01 kcal/mol Å and saved in PDBQT format (A modification of the protein data bank format especially developed to hold the information needed by the protein-ligand docking software AutoDock, including the assigned charges). Co-crystal structures for human N-terminal maltase-glucoamylase ntMGAM (PDB:2QMJ), human C-terminal maltase-glucoamylase ctMGAM (PDB:3TOP), and human N-terminal sucrose-isomaltase ntSI (PDB:3LPP) were downloaded from the protein data bank (https://www.rcsb.org). All target receptors were prepared using MGL tools v1.5.7 to perform the deletion of water molecules and other heteratoms, the addition of polar hydrogens, and the addition of Kollman Charges, then saved in PDBQT format. Grid boxes were centered at the co-crystalized ligands with dimensions 30 × 30 × 30 Å to accommodate the whole binding sites of the target receptors. All docking calculations were implemented with the aid of the open-source software AutoDock vina v1.1.2. The docking poses were ranked according to their docking scores, and the best energy pose was selected. The interactions between the screened compound and the target proteins were analyzed using Discovery Studio Visualizer v21.1.0.20298 [16].

RESULTS AND DISCUSSION

The CH₂Cl₂ and EtOAc fractions derived from T. myriocarpa methanolic leaf extract were found to exhibit α-glucosidase inhibitory activity (Table 1). The EtOAc fraction exhibited potent activity with an half-maximal inhibitory concentration (IC₅₀) value of 0.49 ± 0.03 µg/ml. The CH₂Cl₂, and EtOAc fractions were subjected to further phytochemical analysis, which led to the isolation of compounds 1 through 10 due to their separation using variable chromatographic procedures. The structures of the isolates were determined by spectral means (UV, 1H-, and 13C-NMR) and acid hydrolysis. Among these, compounds 1 [17,18], 4 [19,20], 6 [21], and 8 [22,23] are recorded herein for the first time from the genus Terminalia. In addition, this report is the first to mention the occurrence of compounds 7 [24,25], 9 [21], and 10 [26] in T. myriocarpa. Compounds 7, 9, and 10 were previously isolated from Terminalia arjuna bark [27], Terminalia catappa leaves [28], and Terminalia chebula fruits [29], respectively. On the other hand, compounds 2 [30,31], 3 [32], and 5 [31,33] were previously reported from the leaves of T. myriocarpa [2]. Results of evaluation of the α-glucosidase inhibitory potential of the isolated compounds (Table 2) revealed that quercetin and flavogallonic acid with IC₅₀ values equal to 7.5 ± 0.09 and 21.0 ± 1.4 µM, respectively, might be responsible for the activity of the EtOAc fraction. This was in agreement with earlier reports on the ability of quercetin to inhibit α-glucosidase, with an IC₅₀ value of 7 µM, through the formation of hydrogen bond interactions with the active site pocket of the enzyme [34,35]. Furthermore, former studies indicated that arjunic acid [11], nigaichigoside F1, rosamultin, and 19α-hydroxyasaiatic acid [36] do not significantly inhibit α-glucosidase enzyme, which agreed with our findings. Moreover, isovitexin and asiatic acid were reported to exert α-glucosidase inhibitory effects with IC₅₀ values of 266.2 µM [37] and 100.2 ± 4.2 µM [38], respectively, which confirmed our results on the weak α-glucosidase inhibitory effects of these compounds. On the other hand, nothing could be traced in the literature concerning the α-glucosidase inhibitory activity of flavogallonic acid, alphitolic acid, and quadranoside IV. Therefore, to predict the mode of binding of flavogallonic acid to human α-glucosidase, a docking study with human C-terminal maltase-glucoamylase ctMGAM (PDB:3TOP), human N-terminal maltase-glucoamylase ntMGAM (PDB:2QMJ), and

Table 1. α-Glucosidase inhibitory activity of the CH₂Cl₂ and EtOAc fractions derived from T. myriocarpa methanolic leaf extract.

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC₅₀ (µg/ml) ± SD (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH₂Cl₂ fraction</td>
<td>58.31 ± 1.22</td>
</tr>
<tr>
<td>EtOAc fraction</td>
<td>0.49 ± 0.03</td>
</tr>
<tr>
<td>Acarbose (positive control)</td>
<td>10.6 ± 0.09</td>
</tr>
</tbody>
</table>

IC₅₀: Half-maximal inhibitory concentration. CH₂Cl₂: Dichloromethane, EtOAc: Ethyl acetate.

Results are represented as the mean value of three independent experiments ± standard deviation (SD).

Table 2. α-Glucosidase inhibitory activity of the isolated compounds from T. myriocarpa methanolic leaf extract.

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC₅₀ (µM) ± SD (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alphitolic acid</td>
<td>&gt;700</td>
</tr>
<tr>
<td>Isovitexin</td>
<td>&gt;700</td>
</tr>
<tr>
<td>Flavogallonic acid</td>
<td>21.0 ± 1.4</td>
</tr>
<tr>
<td>Nigaichigoside F1</td>
<td>&gt;700</td>
</tr>
<tr>
<td>Quercetin</td>
<td>7.5 ± 0.09</td>
</tr>
<tr>
<td>Quadranoside IV</td>
<td>&gt;700</td>
</tr>
<tr>
<td>Rosamultin</td>
<td>&gt;700</td>
</tr>
<tr>
<td>19α-hydroxyasiatic acid</td>
<td>&gt;700</td>
</tr>
<tr>
<td>Asiatic acid</td>
<td>&gt;700</td>
</tr>
<tr>
<td>Arjunic acid</td>
<td>&gt;700</td>
</tr>
<tr>
<td>Acarbose (positive control)</td>
<td>16.42 ± 0.14</td>
</tr>
</tbody>
</table>

IC₅₀: Half-maximal inhibitory concentration. Results are represented as the mean value of three independent experiments ± standard deviation (SD).
isolated from the EtOAc fraction of *T. myriocarpa* methanolic leaf extract, point to their possible use as lead compounds to develop α-glucosidase inhibitors. This could only be implemented after confirming the obtained findings by assessing their efficacy and toxicity *in-vivo*.

**ACKNOWLEDGMENTS**

The authors are grateful to Ms. Therese Labib, the taxonomical consultant at Orman Botanical Garden and El Qubba Botanical Garden, for the identification and authentication of the plant material.

**AUTHOR CONTRIBUTIONS**

All authors have participated in designing the study, collection, and analysis of data, as well as writing the manuscript, which was approved by all authors.

**CONFLICTS OF INTEREST**

The authors declare that there are no conflicts of interest.

**FINANCIAL SUPPORT**

The National Research Centre, Giza, Egypt, provided this work’s funding.

**ETHICAL APPROVALS**

This study was carried out upon approval of the “Medical Research Ethics Committee” of the National Research Centre, Giza, Egypt (Registration number: 20115).

**DATA AVAILABILITY**

All the obtained and interpreted data are included in this research article.

**PUBLISHER’S NOTE**

This journal remains neutral with regard to jurisdictional claims in published institutional affiliation.

**REFERENCES**

Terminalia bellerica Retz. and their biosynthesis of natural and novel C-glycosylflavones.


How to cite this article: